SAB Biotherapeutics (SABSW) Gains from Sales and Divestitures (2023 - 2025)
Historic Gains from Sales and Divestitures for SAB Biotherapeutics (SABSW) over the last 3 years, with Q3 2025 value amounting to $12544.0.
- SAB Biotherapeutics' Gains from Sales and Divestitures fell 5997.83% to $12544.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12544.0, marking a year-over-year decrease of 5997.83%. This contributed to the annual value of $22709.0 for FY2024, which is 7719.26% up from last year.
- As of Q3 2025, SAB Biotherapeutics' Gains from Sales and Divestitures stood at $12544.0, which was down 5997.83% from $8364.0 recorded in Q2 2025.
- SAB Biotherapeutics' Gains from Sales and Divestitures' 5-year high stood at $106250.0 during Q3 2023, with a 5-year trough of $4183.0 in Q1 2025.
- In the last 3 years, SAB Biotherapeutics' Gains from Sales and Divestitures had a median value of $22843.5 in 2024 and averaged $32334.7.
- Per our database at Business Quant, SAB Biotherapeutics' Gains from Sales and Divestitures skyrocketed by 7719.26% in 2024 and then tumbled by 8179.56% in 2025.
- Over the past 3 years, SAB Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $12816.0 in 2023, then surged by 77.19% to $22709.0 in 2024, then plummeted by 44.76% to $12544.0 in 2025.
- Its Gains from Sales and Divestitures was $12544.0 in Q3 2025, compared to $8364.0 in Q2 2025 and $4183.0 in Q1 2025.